• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测 I 期肝内胆管细胞癌切除术后复发的风险。

Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma.

机构信息

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan; Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and The James Comprehensive Cancer Center, Columbus, OH, United States.

出版信息

J Gastrointest Surg. 2024 Jan;28(1):18-25. doi: 10.1016/j.gassur.2023.10.002.

DOI:10.1016/j.gassur.2023.10.002
PMID:38353070
Abstract

BACKGROUND

Early-stage intrahepatic cholangiocarcinoma (ICC) is often an indication of curative-intent resection. Although patients with early-stage ICC generally have a better prognosis than individuals with advanced ICC, the incidence and risk factors of recurrence after early-stage ICC remain unclear.

METHODS

A multi-institutional database was used to identify patients who underwent surgery between 2000 and 2018 for ICC with pathologically confirmed stage I disease. Cox regression analysis was used to identify clinicopathological factors associated with recurrence, and an online prediction model was developed and validated.

RESULTS

Of 430 patients diagnosed with stage I ICC, approximately one-half of patients (n = 221, 51.4%) experienced recurrence after curative-intent resection. Among patients with a recurrence, most (n = 188, 85.1%) experienced it within 12 months. On multivariable analysis, carcinoembryonic antigen (hazard ratio [HR], 1.011; 95% CI, 1.004-1.018), systemic immune-inflammation index (HR, 1.036; 95% CI, 1.019-1.056), no lymph nodes evaluated (HR, 1.851; 95% CI, 1.276-2.683), and tumor size (HR, 1.101; 95% CI, 1.053-1.151) were associated with greater hazards of recurrence. A predictive model that included these weighted risk factors demonstrated excellent prognostic discrimination in the test (12-month recurrence-free survival [RFS]: low risk, 80.1%; intermediate risk, 60.3%; high risk, 37.7%; P = .001) and validation (12-month RFS: low risk, 84.5%; intermediate risk, 63.5%; high risk, 47.1%; P = .036) datasets. The online predictive model was made available at https://ktsahara.shinyapps.io/stageI_icc/.

CONCLUSIONS

Patients with stage I ICC without vascular invasion or lymph node metastasis had a relatively high incidence of recurrence. An online tool can risk stratify patients relative to recurrence risk to identify individuals best suited for alternative treatment approaches.

摘要

背景

早期肝内胆管癌(ICC)通常是根治性切除的指征。尽管早期 ICC 患者的预后一般优于晚期 ICC 患者,但早期 ICC 后复发的发生率和危险因素仍不清楚。

方法

使用多机构数据库,确定 2000 年至 2018 年间接受病理证实为 I 期疾病的 ICC 手术治疗的患者。采用 Cox 回归分析确定与复发相关的临床病理因素,并开发和验证在线预测模型。

结果

在 430 例诊断为 I 期 ICC 的患者中,约一半(n=221,51.4%)在根治性切除后复发。在复发的患者中,大多数(n=188,85.1%)在 12 个月内复发。多变量分析显示,癌胚抗原(HR,1.011;95%CI,1.004-1.018)、系统免疫炎症指数(HR,1.036;95%CI,1.019-1.056)、未评估的淋巴结(HR,1.851;95%CI,1.276-2.683)和肿瘤大小(HR,1.101;95%CI,1.053-1.151)与复发风险增加相关。包含这些加权风险因素的预测模型在测试(12 个月无复发生存率[RFS]:低危,80.1%;中危,60.3%;高危,37.7%;P=0.001)和验证(12 个月 RFS:低危,84.5%;中危,63.5%;高危,47.1%;P=0.036)数据集中均具有良好的预后判别能力。在线预测模型可在 https://ktsahara.shinyapps.io/stageI_icc/ 获得。

结论

无血管侵犯或淋巴结转移的 I 期 ICC 患者复发率相对较高。在线工具可以对患者的复发风险进行分层,以确定最适合替代治疗方法的个体。

相似文献

1
Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma.预测 I 期肝内胆管细胞癌切除术后复发的风险。
J Gastrointest Surg. 2024 Jan;28(1):18-25. doi: 10.1016/j.gassur.2023.10.002.
2
Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma.微血管侵犯对肝内胆管癌根治性切除术后临床结局的影响。
J Surg Oncol. 2019 Jan;119(1):21-29. doi: 10.1002/jso.25305. Epub 2018 Nov 22.
3
Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.肝内胆管癌根治性切除术后的分期、预后因素及辅助治疗
Liver Int. 2014 Jul;34(6):953-60. doi: 10.1111/liv.12364. Epub 2013 Nov 20.
4
Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches.肝内胆管细胞癌切除术后早期复发:考虑替代治疗方法。
JAMA Surg. 2020 Sep 1;155(9):823-831. doi: 10.1001/jamasurg.2020.1973.
5
Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.根治性切除术后肝内胆管细胞癌的复发模式和时间进程。
Ann Surg Oncol. 2019 Aug;26(8):2549-2557. doi: 10.1245/s10434-019-07353-4. Epub 2019 Apr 24.
6
Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.肝内胆管癌:手术切除后的预后因素
World J Surg. 2009 Jun;33(6):1247-54. doi: 10.1007/s00268-009-9970-0.
7
[The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].[术前外周血炎症生物标志物对肝内胆管癌根治性切除术后的预后价值]
Zhonghua Zhong Liu Za Zhi. 2022 Nov 23;44(11):1194-1201. doi: 10.3760/cma.j.cn112152-20210324-00265.
8
Prognosis after resection for hepatitis B virus-associated intrahepatic cholangiocarcinoma.乙型肝炎病毒相关性肝内胆管癌切除术后的预后
World J Gastroenterol. 2015 Jan 21;21(3):935-43. doi: 10.3748/wjg.v21.i3.935.
9
Long-term survivors after curative-intent resection for intrahepatic cholangiocarcinoma.肝内胆管细胞癌根治性切除术后的长期生存者。
J Surg Oncol. 2024 Sep;130(3):443-452. doi: 10.1002/jso.27739. Epub 2024 Jun 18.
10
Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study.开发和验证一种新的预后免疫炎症营养评分,用于预测肝内胆管癌根治性切除术后的结局:一项多中心研究。
Front Immunol. 2023 Mar 31;14:1165510. doi: 10.3389/fimmu.2023.1165510. eCollection 2023.

引用本文的文献

1
Endoscopic Ablation in Cholangiocarcinoma.胆管癌的内镜下消融治疗
Cancers (Basel). 2025 Aug 29;17(17):2843. doi: 10.3390/cancers17172843.
2
ASO Author Reflections: Occult Nodal Disease in Intrahepatic Cholangiocarcinoma-Implications of a Preoperative Inflammatory Biomarker.ASO作者反思:肝内胆管癌中的隐匿性淋巴结疾病——术前炎症生物标志物的意义
Ann Surg Oncol. 2025 Jul 19. doi: 10.1245/s10434-025-17891-9.
3
Oncological Resectability Criteria for Intrahepatic Cholangiocarcinoma: A Preoperative Framework for Multidisciplinary Management.
肝内胆管癌的肿瘤可切除性标准:多学科管理的术前框架
Ann Surg Oncol. 2025 Jul 9. doi: 10.1245/s10434-025-17776-x.
4
Preoperative Systemic Immune-Inflammatory Index Predicts Occult Nodal Disease in Clinically Node-Negative Intrahepatic Cholangiocarcinoma.术前全身免疫炎症指数可预测临床淋巴结阴性肝内胆管癌的隐匿性淋巴结疾病。
Ann Surg Oncol. 2025 Jul 9. doi: 10.1245/s10434-025-17781-0.
5
Impact of Tumor Size on the Survival Benefit of Anatomic Versus Non-Anatomic Resection for Intrahepatic Cholangiocarcinoma.肿瘤大小对肝内胆管癌解剖性切除与非解剖性切除生存获益的影响
Ann Surg Oncol. 2025 Apr 15. doi: 10.1245/s10434-025-17270-4.
6
ASO Author Reflections: Tumor Size as a Determinant of Anatomic Resection Benefit in Intrahepatic Cholangiocarcinoma.ASO作者反思:肿瘤大小作为肝内胆管癌解剖性切除获益的决定因素
Ann Surg Oncol. 2025 Apr 13. doi: 10.1245/s10434-025-17315-8.
7
Preoperative prediction of textbook outcome in intrahepatic cholangiocarcinoma by interpretable machine learning: A multicenter cohort study.通过可解释机器学习对肝内胆管癌教科书式预后进行术前预测:一项多中心队列研究
World J Gastroenterol. 2025 Mar 21;31(11):100911. doi: 10.3748/wjg.v31.i11.100911.
8
Predictive model for very early recurrence of patients with perihilar cholangiocarcinoma: a machine learning approach.肝门部胆管癌患者极早期复发的预测模型:一种机器学习方法
Hepatobiliary Surg Nutr. 2025 Feb 1;14(1):3-15. doi: 10.21037/hbsn-24-385. Epub 2025 Jan 16.